NCT04702802View on ClinicalTrials.gov

Clinical Study to Evaluate the Safety of the Viscoelastic Substance PRO-149 When Used During Phacoemulsification, Compared to Healon® EndoCoat.

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions
Age-related CataractPhacoemulsification
Interventions
DEVICE

Sodium hyaluronate 3%

During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.

DEVICE

Sodium hyaluronate 3%

During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.

Trial Locations (1)

Unknown

SalaUno Salud, S.A.P.I. de C.V., Mexico City

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY

NCT04702802 - Clinical Study to Evaluate the Safety of the Viscoelastic Substance PRO-149 When Used During Phacoemulsification, Compared to Healon® EndoCoat. | Biotech Hunter | Biotech Hunter